Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein

J Extracell Vesicles. 2023 Mar;12(3):e12312. doi: 10.1002/jev2.12312.


Bone metastases are still incurable and result in the development of clinical complications and decreased survival for prostate cancer patients. Recently, a number of studies have shown that extracellular vesicles (EVs) play important roles in tumour progression. Here, we show that EVs from metastatic prostate cancer cells promote osteoclast formation in the presence of receptor activator of NF-κB ligand (RANKL). EV characterization followed by functional siRNA screening identified CUB-domain containing protein 1 (CDCP1), a transmembrane protein, as an inducer of osteoclastogenesis. Additionally, CDCP1 expression on plasma-derived EVs was upregulated in bone metastatic prostate cancer patients. Our findings elucidate the effect of EVs from metastatic prostate cancer cells on osteoclast formation, which is promoted by CDCP1 located on EVs. Furthermore, our data suggested that CDCP1 expression on EVs might be useful to detect bone metastasis of prostate cancer.

Keywords: CDCP1; extracellular vesicles; osteoclast; prostate cancer.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm
  • Cell Adhesion Molecules
  • Extracellular Vesicles*
  • Humans
  • Male
  • Membrane Proteins
  • Osteoclasts
  • Osteogenesis
  • Prostatic Neoplasms*


  • Membrane Proteins
  • CDCP1 protein, human
  • Antigens, Neoplasm
  • Cell Adhesion Molecules